

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Proteomics International Laboratories Ltd</b>
<b>ABN</b>	<b>78 169 979 971</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Neville Gardiner
<b>Date of last notice</b>	16 November 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect.
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Fertilus Pty Ltd as trustee for The Gardiner Family Trust  Mr Gardiner is director and shareholder of the trustee and a beneficiary of the trust.
<b>Date of change</b>	24 November 2022
<b>No. of securities held prior to change</b>	<i>Direct</i> Nil.  <i>Indirect</i> Nil.
<b>Class</b>	(a) Fully paid ordinary shares ( <b>Shares</b> ). (b) Unquoted options exercisable at \$1.32 per option on or before 24 November 2025 ( <b>Director C Options</b> ). (c) Unquoted options exercisable at \$1.76 per option on or before 24 November 2026 ( <b>Director D Options</b> ).
<b>Number acquired</b>	(a) 117,647 Shares. (b) 250,000 Director C Options. (c) 250,000 Director D Options.

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	Not applicable.
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	(a) \$100,000.  (b) and (c) Non-cash consideration. Issue of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Mr Gardiner's commitment following his appointment as Non-Executive Chairman of the Company.  Estimated value based on an independent valuation: <ul style="list-style-type: none"> <li>• \$101,375 for Director C Options</li> <li>• \$103,575 for Director D Options.</li> </ul>
<b>No. of securities held after change</b>	<i>Direct</i> Nil.  <i>Indirect</i> 117,647 Shares. 250,000 Director C Options. 250,000 Director D Options
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	(a) Participation in placement following receipt of shareholder approval at the annual general meeting held on 24 November 2022 ( <b>2022 AGM</b> ).  (b) and (c) Issue of options following receipt of shareholder approval at the 2022 AGM.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Letter of appointment as Non-Executive Chairman of the Company.
<b>Nature of interest</b>	Offer of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Mr Gardiner's commitment upon appointment as Non-Executive Chairman of the Company.
<b>Name of registered holder (if issued securities)</b>	Fertilus Pty Ltd as trustee for The Gardiner Family Trust
<b>Date of change</b>	24 November 2022

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	Not applicable
<b>Interest acquired</b>	Nil
<b>Interest disposed</b>	Shareholder approval received to issue Director C and Director D Options.
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	Non-cash consideration. Issue of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Mr Gardiner's commitment following his appointment as Non-Executive Chairman of the Company.  Estimated value based on an independent valuation: <ul style="list-style-type: none"> <li>• \$101,375 for Director C Options</li> <li>• \$103,575 for Director D Options.</li> </ul>
<b>Interest after change</b>	<i>Direct</i> Nil.  <i>Indirect</i> 117,647 Shares. 250,000 Director C Options. 250,000 Director D Options

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

+ See chapter 19 for defined terms.

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Proteomics International Laboratories Ltd
<b>ABN</b>	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Robyn Elliott
<b>Date of last notice</b>	16 November 2021

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Not applicable
<b>Date of change</b>	24 November 2022
<b>No. of securities held prior to change</b>	<i>Direct</i> Nil.  <i>Indirect</i> Nil.
<b>Class</b>	(a) Unquoted options exercisable at \$1.32 per option on or before 24 November 2025 ( <b>Director C Options</b> ). (b) Unquoted options exercisable at \$1.76 per option on or before 24 November 2026 ( <b>Director D Options</b> ).
<b>Number acquired</b>	(a) 125,000 Director C Options. (b) 125,000 Director D Options.
<b>Number disposed</b>	Not applicable.

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Value/Consideration</b>          Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Non-cash consideration. Issue of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Dr Elliott's commitment following her appointment as a non-executive director of the Company.</p> <p>Estimated value based on an independent valuation:</p> <ul style="list-style-type: none"> <li>• \$50,688 for Director C Options</li> <li>• \$51,788 for Director D Options.</li> </ul>
<p><b>No. of securities held after change</b></p>	<p><i>Direct</i>          Nil.</p> <p><i>Indirect</i>          125,000 Director C Options.          125,000 Director D Options</p>
<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of options following receipt of shareholder approval at the annual general meeting held on 24 November 2022.</p>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p><b>Detail of contract</b></p>	<p>Letter of appointment as a non-executive director.</p>
<p><b>Nature of interest</b></p>	<p>Offer of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Dr Elliott's commitment upon appointment as a non-executive director of the Company.</p>
<p><b>Name of registered holder (if issued securities)</b></p>	<p>Robyn Elliott</p>
<p><b>Date of change</b></p>	<p>24 November 2022</p>
<p><b>No. and class of securities to which interest related prior to change</b>          Note: Details are only required for a contract in relation to which the interest has changed</p>	<p>Not applicable</p>
<p><b>Interest acquired</b></p>	<p>Nil</p>
<p><b>Interest disposed</b></p>	<p>Shareholder approval received to issue Director C and Director D Options.</p>

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation</p>	<p>Non-cash consideration. Issue of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Dr Elliott's commitment following her appointment as a non-executive director of the Company.</p> <p>Estimated value based on an independent valuation:</p> <ul style="list-style-type: none"> <li>• \$50,688 for Director C Options</li> <li>• \$51,788 for Director D Options.</li> </ul>
<p><b>Interest after change</b></p>	<p><i>Direct</i> Nil.</p> <p><i>Indirect</i> 125,000 Director C Options. 125,000 Director D Options</p>

**Part 3 - +Closed period**

<p><b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b></p>	<p>No.</p>
<p><b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b></p>	
<p><b>If prior written clearance was provided, on what date was this provided?</b></p>	

---

+ See chapter 19 for defined terms.

For personal use only

Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Proteomics International Laboratories Ltd</b>
<b>ABN</b>	<b>78 169 979 971</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Paul Edward House
<b>Date of last notice</b>	24 October 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Baljuna Capital Pty Ltd  Mr House is a shareholder and director of the entity.
<b>Date of change</b>	24 November 2022
<b>No. of securities held prior to change</b>	<i>Direct</i> 343,864 fully paid ordinary shares (Shares).  <i>Indirect</i> 575,000 Shares.
<b>Class</b>	Shares.
<b>Number acquired</b>	117,647 Shares.
<b>Number disposed</b>	Not applicable.
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$100,000
<b>No. of securities held after change</b>	<i>Direct</i> 343,864 Shares.  <i>Indirect</i> 692,647 Shares.

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Participation in placement following receipt of shareholder approval at the annual general meeting held on 24 November 2022.</p>
--	---

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable.
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<p><b>No. and class of securities to which interest related prior to change</b>          Note: Details are only required for a contract in relation to which the interest has changed</p>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<p><b>Value/Consideration</b>          Note: If consideration is non-cash, provide details and an estimated valuation</p>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Not applicable
<b>If prior written clearance was provided, on what date was this provided?</b>	Not applicable

+ See chapter 19 for defined terms.

For personal use only



# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Proteomics International Laboratories Ltd</b>
<b>ABN</b>	<b>78 169 979 971</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ian Roger Moore
<b>Date of last notice</b>	24 October 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect.
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Moore and Sotomi Investments Pty Ltd as trustee for the Roger Moore Family A/C  Mr Moore is a director and shareholder of the trustee and a beneficiary of the trust.
<b>Date of change</b>	24 November 2022
<b>No. of securities held prior to change</b>	<i>Direct</i> Nil.  <i>Indirect</i> 917,000 fully paid ordinary shares ( <b>Shares</b> ).
<b>Class</b>	Shares.
<b>Number acquired</b>	58,824 Shares.
<b>Number disposed</b>	Not applicable.
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$50,000

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<i>Direct</i> Nil.  <i>Indirect</i> 975,824 Shares.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in placement following receipt of shareholder approval at the annual general meeting held on 24 November 2022.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable.
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

+ See chapter 19 for defined terms.

For personal use only